Sign in
Taking peoplePhase 3

A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections

Key facts

Who runs it
Basilea Pharmaceutica International AG Allschwil
Where
Austria, Belgium, France, Germany, Greece, Italy, Netherlands, and Spain38 sites in 8 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
94 people, planned
Started
13 Feb 2026
Expected to end
1 Feb 2028
Type of study
Interventional
Record updated
14 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Diagnosis of proven or probable IMI defined in accordance with the Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the EORTC/MSGERC as adapted for this study and caused by Aspergillus spp. (in patients with limited treatment options), Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multi-drug resistant molds
  • Patient’s condition allows for appropriate infection source control measures

Who cannot take part

  • Current use of any prohibited concomitant medication(s)
  • Current/previous administration of an investigational drug within 30 days
  • Prior enrollment in this or any previous study of fosmanogepix
  • Patients receiving hospice/comfort care only
  • Refractory hematologic malignancy
  • Other medical or psychiatric condition
  • Moderate or severe hepatic impairment
  • Known hypersensitivity to fosmanogepix, manogepix, or any of the excipients
  • Chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis
  • Coronavirus disease 2019 (COVID-19) associated mucormycosis
  • Invasive fungal disease caused by more than one fungal pathogen are not permitted in Cohort A but are permitted in Cohort B
  • Patients with known human immunodeficiency virus infection
  • Ongoing neurological disorders
  • Patient who is pregnant or lactating
  • Patients with a Karnofsky Performance Status < 20 at Screening
  • Requirement, or anticipated requirement, for hemodialysis, peritoneal dialysis, or hemofiltration

This trial has no sites in United States.

It has sites in 8 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy of fosmanogepix for the treatment of adult patients with Invasive mold infections (IMIs) caused by Aspergillus spp. (in patients with limited treatment options), Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds
Record updated
14 September 2026